오피오이드 유발성 변비 시장 : 시장 규모, 점유율 및 성장 분석 - 약제 클래스별, 투여 경로별, 유통 경로별, 최종 사용자별, 지역별 업계 예측(2026-2033년)

Global Opioid Induced Constipation Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.63 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 7.22% during the forecast period (2026-2033).

The global opioid-induced constipation (OIC) market encompasses a range of pharmaceuticals, devices, and supportive therapies addressing bowel dysfunction resulting from chronic opioid use. Its significance is largely attributed to the reliance on opioids for managing various pain types, leading to constipation in a substantial majority of patients. The market's growth is driven by increased awareness of opioid-related adverse events within healthcare systems, translating into higher demand for evidence-based treatment options. Furthermore, insurers linking reimbursements to care quality propels the adoption of peripheral μ-opioid antagonists. Innovative AI-driven analytics enhance patient management by enabling real-time monitoring and tailoring interventions, fostering improved care coordination among healthcare providers. This holistic approach ultimately aims to enhance patient adherence and overall quality of life while optimizing healthcare resource utilization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioid Induced Constipation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioid Induced Constipation Market Segments Analysis

The global opioid-induced constipation market is segmented based on drug class, route of administration, distribution channel, end-user, and region. By drug class, the market is categorized into Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs), Laxatives, and Chloride Channel Activators. Based on route of administration, the market is divided into Oral and Subcutaneous therapies. By distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on end-user, the market is classified into Hospitals, Palliative Care Centers, and Pain Clinics. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Opioid Induced Constipation Market

The surge in opioid prescriptions for managing chronic pain, post-operative recovery, and palliative care has significantly broadened the number of patients susceptible to opioid-induced constipation. Healthcare professionals are increasingly recognizing constipation as more than just a symptom; they view it as a significant quality-of-life issue, prompting them to seek specialized therapies for affected individuals. This heightened clinical awareness drives the demand for pharmaceutical solutions and products designed to alleviate bowel dysfunction, consequently fostering market growth. As the adoption of targeted treatments becomes standard in pain management practices, pharmaceutical companies are investing in expanding their product lines, funding educational initiatives, and collaborating with healthcare providers to ensure a seamless integration of these therapies.

Restraints in the Global Opioid Induced Constipation Market

The Global Opioid Induced Constipation market faces significant challenges due to rigorous regulatory requirements for therapy approval and labeling. The necessity for extensive documentation and thorough safety evaluations complicates the development process, as regulators demand substantial evidence of efficacy, low systemic absorption, and minimal risk of abuse. This complexity not only extends development timelines but also increases costs, which can dissuade smaller innovators from entering the market and consequently limit the variety of available treatment options. Despite a growing clinical need, these factors can hinder overall market expansion, and the ongoing requirement for post-marketing surveillance adds further delays in the adoption of new products.

Market Trends of the Global Opioid Induced Constipation Market

The Global Opioid Induced Constipation market is experiencing a noteworthy shift towards integrated digital therapeutics. This emerging trend highlights the rapid adoption of digital health platforms for enhancing patient management, enabling remote monitoring of bowel activity, and facilitating personalized dosage adjustments in real time. Clinicians leverage AI-driven analytics to anticipate symptom progression, while patients engage with mobile applications that provide ongoing coaching and education. This innovative fusion of pharmacological therapy and technology promotes a proactive care approach, accelerates therapy optimization, and enhances accessibility through telehealth, positioning digital therapeutics as a crucial growth driver in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Opioid Induced Constipation Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• PAMORAs (Peripherally Acting Mu-Opioid Receptor Antagonists)
• Laxatives
• Chloride Channel Activators

Global Opioid Induced Constipation Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Subcutaneous

Global Opioid Induced Constipation Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Opioid Induced Constipation Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Palliative Care
• Pain Clinics

Global Opioid Induced Constipation Market Size & CAGR (2026-2033)

• North America (Drug Class, Route, Distribution, End-User)
  • US
  • Canada
• Europe (Drug Class, Route, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (Movantik)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Salix Pharmaceuticals (Relistor)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health (Relistor)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi USA (Symproic)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nektar Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenics Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actavis (Allergan/AbbVie)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norgine BV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sucampo Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synergy Pharmaceuticals (Bausch)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ironwood Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ardelyx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RedHill Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations